Trials Sponsors Conditions Drugs Pricing

Conditions

Advanced Solid Tumor

Outcome Measures

Primary Outcomes (3)

Proportion of subjects with dose-limiting toxicity (DLT)
Number of subjects who experienced DLT events during 28 days after first administration of EOC237, divided by the number of DLT evaluable Subjects
Up to approximately 3 years
Determination of maximum tolerated dose (MTD)
Up to approximately 3 years
the recommended phase 2 dose (RP2D)
Up to approximately 3 years

Study Arms (3)

Part 1: Dose Escalation

EXPERIMENTAL

In Part 1 (dose escalation) participants with selected advanced solid tumors will receive escalating doses of EOC237 as monotherapy. Participants can receive EOC237 until disease progression, adverse event (AE), or other discontinuation criteria, whichever occurs first.

Drug: EOC237

Part 2: Food influence-Group 1

EXPERIMENTAL

Food influence-Group 1: EOC237 was taken orally under fasted conditions, after a 3-day washout period, EOC237 was taken orally under fed conditions. Participants can receive EOC237 until disease progression, AE, or other discontinuation criteria, whichever occurs first.

Drug: EOC237

Part 2: Food influence-Group 2

EXPERIMENTAL

Interventions

EOC237Drug

EOC237 for orally

Part 1: Dose EscalationPart 2: Food influence-Group 1Part 2: Food influence-Group 2

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Advanced Solid Tumors for which standard curative or palliative measures do not exist or are no longer effective.
Expected survival≥ 3 months.

Sponsors & Collaborators

Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
Industrylead

Study Sites (1)

National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, 100029, China

RECRUITING

Binghe XuCONTACT+861087788495 cancergcp@163.com

Central Study Contacts

Binghe Xu, MD

CONTACT

8610-87788495 cancergcp@163.com

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SEQUENTIAL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

May 12, 2023

First Posted

June 9, 2023

Study Start

July 26, 2023

Actual (reported)

Primary Completion

April 30, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

A Study of EOC237 in Patients With Advanced Solid Tumor

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (3)

Study Arms (3)

Part 1: Dose Escalation

Part 2: Food influence-Group 1

Part 2: Food influence-Group 2

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (3)

Study Arms (3)

Part 1: Dose Escalation

Part 2: Food influence-Group 1

Part 2: Food influence-Group 2

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations